2025 United States Antibodies In Oncology Market Revenue Opportunities Report
Description
The 2025 United States Antibodies In Oncology Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibodies in oncology market in the United States are Roche, Amgen, Merck, and AstraZeneca. Roche, a Swiss multinational with a strong oncology portfolio including therapeutic antibodies like Rituxan and Herceptin, leads innovation in targeted cancer therapies and bispecific antibodies. Amgen, the largest independent biotech company based in Thousand Oaks, California, focuses on recombinant DNA technology for cancer treatment and recently expanded through acquisitions like ChemoCentryx, bolstering its oncology pipeline. Merck is advancing dual-targeting bispecific antibodies and immuno-oncology drugs, with a notable focus on next-generation therapies activating the immune system against cancer. AstraZeneca, known for its robust immuno-oncology portfolio, is developing antibody-drug conjugates (ADCs) and novel bispecific antibodies, with significant clinical trial activity in lung and other cancers.
These companies dominate the U.S. oncology antibody market through a combination of extensive research and development, clinical trial progress, and strategic acquisitions. Roche and Merck emphasize bispecific and immuno-oncology antibodies, aiming to improve treatment efficacy by engaging multiple immune pathways. Amgen leverages molecular biology expertise and expands its biologics pipeline through targeted deals. AstraZeneca, collaborating with partners like Daiichi Sankyo, is poised to introduce new ADC therapies with promising trial results in 2025, strengthening its position in the ADC oncology segment. Together, these firms drive innovation in antibodies for cancer treatment, contributing significantly to the anticipated market growth.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies in Oncology Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antibodies in oncology market in the United States are Roche, Amgen, Merck, and AstraZeneca. Roche, a Swiss multinational with a strong oncology portfolio including therapeutic antibodies like Rituxan and Herceptin, leads innovation in targeted cancer therapies and bispecific antibodies. Amgen, the largest independent biotech company based in Thousand Oaks, California, focuses on recombinant DNA technology for cancer treatment and recently expanded through acquisitions like ChemoCentryx, bolstering its oncology pipeline. Merck is advancing dual-targeting bispecific antibodies and immuno-oncology drugs, with a notable focus on next-generation therapies activating the immune system against cancer. AstraZeneca, known for its robust immuno-oncology portfolio, is developing antibody-drug conjugates (ADCs) and novel bispecific antibodies, with significant clinical trial activity in lung and other cancers.
These companies dominate the U.S. oncology antibody market through a combination of extensive research and development, clinical trial progress, and strategic acquisitions. Roche and Merck emphasize bispecific and immuno-oncology antibodies, aiming to improve treatment efficacy by engaging multiple immune pathways. Amgen leverages molecular biology expertise and expands its biologics pipeline through targeted deals. AstraZeneca, collaborating with partners like Daiichi Sankyo, is poised to introduce new ADC therapies with promising trial results in 2025, strengthening its position in the ADC oncology segment. Together, these firms drive innovation in antibodies for cancer treatment, contributing significantly to the anticipated market growth.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
